FDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast…
Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people…
Read More...
Read More...
